Moderna to potentially supply Japan with 40M doses of COVID-19 vaccine

By The Science Advisory Board staff writers

August 28, 2020 -- Moderna is in discussion with the Ministry of Health, Labour, and Welfare of Japan (MHLW) to potentially purchase 40 million or more doses of its messenger RNA (mRNA) vaccine candidate against COVID-19 to support Japan's efforts in securing vaccines as soon as possible.

Under the agreement, Moderna would supply mRNA-1273 and Takeda Pharmaceutical Company would distribute it in the first half of 2021, upon successful regulatory approval, said Kato Katsunobu, minister of MHLW, in a meeting on August 28.

If you like this content, please share it with a colleague!

Related Reading

Moderna discusses supplying 80M doses of mRNA-1273 to EU
Moderna is in discussions with the European Commission to supply 80 million doses of messenger RNA (mRNA)-1273, Moderna's COVID-19 vaccine candidate,...

U.S. to pay $1.5B for Moderna's COVID-19 vaccine
The U.S. government awarded a maximum $1.525 billion contract to Moderna to secure 100 million doses of its messenger RNA COVID-19 vaccine.

Amazon powers Moderna's digital biotech platform
Amazon Web Services is providing cloud, analytics, and machine-learning services to Moderna for its messenger RNA platform and manufacturing facility.

Animal study turns in positive results for Moderna-NIH COVID-19 vaccine
Moderna's COVID-19 vaccine candidate, messenger RNA (mRNA)-1273, has been shown to induce immune responses and control upper and lower respiratory tract...

Moderna begins phase III testing of COVID-19 vaccine
Moderna has begun a phase III clinical trial evaluating its messenger RNA (mRNA)-1273 COVID-19 vaccine candidate. The trial is expected to enroll approximately...